BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2015 4:38:00 PM | Browse: 1287 | Download: 1524
 |
Received |
|
2014-07-06 13:59 |
|
Peer-Review Started |
|
2014-07-07 13:04 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-07-25 09:16 |
|
Revised |
|
2014-07-29 15:24 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-11-11 10:07 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-11-11 10:23 |
|
Articles in Press |
|
2014-11-11 10:59 |
|
Edit the Manuscript by Language Editor |
|
2014-12-22 01:43 |
|
Typeset the Manuscript |
|
2015-02-02 13:46 |
|
Publish the Manuscript Online |
|
2015-02-11 16:38 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jean-Florian Guion-Dusserre, Veronique Lorgis, Julie Vincent, Leila Bengrine and Francois Ghiringhelli |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Francois Ghiringhelli, MD, PhD, Department of Medical Oncology, Centre Georges-François Leclerc, INSERM Avenir 866, 1 rue du Professeur Marion, 21000 Dijon,
France. fghiringhelli@cgfl.fr
|
| Key Words |
Biliary tract cancer; Intrahepatic cholangiocarcinoma; FOLFIRI; Bevacizumab; Second-line treatment |
| Core Tip |
This retrospective study tests the efficacy of FOLFIRI plus bevacizumab as second-line treatment for metastatic cholangiocarcinoma. We observed that this particular chemotherapy treatment gives good response rates and prolongs survival.
|
| Publish Date |
2015-02-11 16:38 |
| Citation |
Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i7/2096.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i7.2096 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
